PEGPH20: Ph Ib/II S1313 data

Halozyme said it was informed by the Southwest Oncology Group that the U.S. Phase Ib/II S1313 trial evaluating 3 µg/kg IV PEGPH20 every 2 weeks plus modified FOLFIRINOX chemotherapy vs. modified FOLFIRINOX alone in previously untreated metastatic pancreatic cancer patients has been temporarily closed to enrollment. During a planned futility analysis, an independent DMC said preliminary data showed that PEGPH20 plus modified FOLFIRINOX was unlikely to show a significant improvement on the primary endpoint of OS vs. modified FOLFIRINOX alone. Halozyme said it is working with the Southwest Oncology Group to analyze the data. The trial was slated to enroll about 172 patients...